BTIG downgraded Mersana Therapeutics (MRSN) to Neutral from Buy following news this morning of Mersana’s acquisition by Day One Biopharmaceuticals (DAWN) for $25 per share in cash at closing plus one non-tradable CVR per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics up 201% at $26.70 after being acquired by Day One Biopharma
- Mersana Therapeutics downgraded to Neutral from Outperform at Wedbush
- Why Is Mersana Therapeutics Stock (MRSN) Up Today?
- Mersana Therapeutics Announces Merger with Day One
- Day One Biopharmaceuticals to acquire Mersana Therapeutics for up to $285M